Agilent Technologies, Inc. | Authors

Wednesday, May 25, 2022 at 11am EDT|8am PDT|5pm CEST|4pm BST In the last few years, the issuance of the ISO 10993-18:2020 medical device guidance and several high-profile publications and round robin studies have resulted in the FDA increasing scrutiny of E&L analyses for both drugs and devices. Join our panel of industry experts to discuss these changes and to learn the direction E&L studies may take in the future.